Corcept Therapeutics reports developments in cortisol modulation therapies for severe endocrinologic, oncologic, metabolic and neurologic disorders. The company markets Korlym for endogenous Cushing’s syndrome and Lifyorli, a relacorilant regimen approved with nab-paclitaxel for certain adults with platinum-resistant ovarian, fallopian tube or primary peritoneal cancer.
Recurring news includes financial results, revenue guidance, clinical data from programs such as ROSELLA, DAZALS and MOMENTUM, FDA-related updates, medical-conference presentations, publications, patent matters and distribution arrangements tied to Korlym, Lifyorli and the company’s selective cortisol modulator pipeline.
Summary not available.
Corcept Therapeutics (NASDAQ: CORT) will report first quarter 2026 financial results and provide a corporate update on April 30, 2026. A conference call is scheduled for 5:00 p.m. ET / 2:00 p.m. PT. Participants must register in advance to receive a dial-in and unique access PIN. A listen-only webcast will be available and a replay will be posted on the Investors / Events tab of Corcept.com.
Corcept (NASDAQ: CORT) will present new subgroup overall survival data from the pivotal Phase 3 ROSELLA trial of Lifyorli (relacorilant) plus nab-paclitaxel in platinum-resistant ovarian cancer at ASCO 2026 on May 29, 2026.
Lifyorli was approved by the FDA in March 2026 and is listed as a preferred regimen in NCCN Guidelines for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Corcept (NASDAQ: CORT) presented final Phase 3 ROSELLA results showing Lifyorli (relacorilant) plus nab-paclitaxel reduced risk of death by 35% (HR 0.65; p=0.0004) and extended median overall survival by 4.1 months (16.0 vs 11.9 months) in platinum-resistant ovarian cancer.
The regimen also cut progression risk by 30% (HR 0.70; p=0.0076), was well tolerated versus chemotherapy alone, received FDA approval in March 2026, and was added to NCCN Guidelines as a preferred regimen.
Corcept Therapeutics (NASDAQ: CORT) presented late-breaking MOMENTUM trial data at ACC 2026 showing 27.3% prevalence of endogenous hypercortisolism among 1,086 patients with resistant hypertension (297 patients).
The results align with Corcept’s CATALYST trial and show higher prevalence (32.6%–36.6%) in high‑risk subgroups with elevated HbA1c and multi‑drug blood pressure regimens.
Corcept Therapeutics (NASDAQ: CORT) announced FDA approval on March 25, 2026 for Lifyorli (relacorilant) plus nab-paclitaxel to treat adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer after one to three prior systemic regimens, including at least one with bevacizumab.
Approval followed the 381‑patient ROSELLA trial: OS benefit of 4.1 months (16.0 vs 11.9 months; HR 0.65; p=0.0004) and PFS improvement (HR 0.70; p=0.008). Lifyorli is the first FDA‑approved selective glucocorticoid receptor antagonist; safety notes include neutropenia, infections, adrenal insufficiency and embryo‑fetal toxicity.
Corcept Therapeutics (NASDAQ: CORT) reported 2025 revenue of $761.4M and net income of $99.7M. Fourth-quarter revenue was $202.1M with Q4 net income of $24.3M (diluted EPS $0.20). Cash and investments totaled $532.4M at year-end. Management provided 2026 revenue guidance of $900M–$1,000M and highlighted key clinical readouts, a July 11, 2026 PDUFA date for relacorilant in platinum-resistant ovarian cancer, and plans for a Phase 3 ALS trial.
Corcept (NASDAQ: CORT) said the U.S. Court of Appeals for the Federal Circuit found that Teva Pharmaceuticals’ marketing of a generic Korlym does not infringe two Corcept patents covering methods for safely co-administering Korlym with CYP3A4 inhibitors.
The ruling affirms a December 2023 District Court verdict. Corcept said it is disappointed and is considering whether to seek further judicial review.
Corcept Therapeutics (NASDAQ: CORT) will report fourth quarter and full‑year 2025 financial results and provide a corporate update on February 24, 2026. A conference call and listen‑only webcast will be held at 5:00 p.m. ET (2:00 p.m. PT), with registration required for dial‑in access and PINs.
A replay will be posted on the Investors / Events tab of Corcept.com after the call.
Corcept (NASDAQ: CORT) reported that its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in platinum-resistant ovarian cancer met both dual primary endpoints. The combination reduced the risk of death by 35% (HR 0.65; p=0.0004) and extended median overall survival to 16.0 months vs 11.9 months (difference 4.1 months). ROSELLA also showed a 30% reduction in progression risk (HR 0.70; p=0.008). The regimen was well tolerated with similar adverse event profiles versus nab-paclitaxel alone. The NDA is under FDA review with a PDUFA date of July 11, 2026, and an MAA is under EMA review. ROSELLA enrolled 381 patients randomized 1:1 across multiple regions.